BIOMAT Database Logo BIOMAT Database Logo

Orally administered gallbladder therapeutic agents, Part 1: Chenix (chenodeoxycholic acid, CDCA). 1993

D Wietlispach Claussen

Chenix is an orally administered gallstone solubilizer that reduces biliary cholesterol in the bile acid pool, which in effect helps to dissolve floating radiolucent cholesterol gallstones. Chenix is an agent used to treat cholesterol gallstones in the patient with a higher than average risk for surgical intervention for the removal of gallstones.

UI MeSH Term Description Entries
D002635 Chenodeoxycholic Acid A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones. Chenic Acid,Chenodeoxycholate,Chenodiol,Gallodesoxycholic Acid,Chenique Acid,Chenix,Chenofalk,Chenophalk,Henohol,Quenobilan,Quenocol,Sodium Chenodeoxycholate,Acid, Chenic,Acid, Chenique,Acid, Chenodeoxycholic,Acid, Gallodesoxycholic,Chenodeoxycholate, Sodium
D002769 Cholelithiasis Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS). Gallstone Disease,Cholelithiases,Gallstone Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Wietlispach Claussen
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption.
August 1979, Gastroenterology,
D Wietlispach Claussen
[Positive effects of chenodeoxycholic acid (CDCA) on the biohumoral clinical aspect of cholesterin calculosis of the gallbladder].
March 1978, Minerva medica,
D Wietlispach Claussen
Vitamin D Receptor Deletion Changes Bile Acid Composition in Mice Orally Administered Chenodeoxycholic Acid.
January 2020, Journal of nutritional science and vitaminology,
D Wietlispach Claussen
Method for therapeutic evaluation of diuretic agents administered orally.
July 1953, Journal of the American Medical Association,
D Wietlispach Claussen
Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.
June 1978, British medical journal,
D Wietlispach Claussen
Proceedings: Factors determining gallstone dissolution in patients treated with chenodeoxycholic acid (CDCA).
May 1975, Gut,
D Wietlispach Claussen
[Choleretica properties of chenodeoxycholic acid CDCA and dehydrocholic acid (DHCA) in rats (author's transl)].
January 1980, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
D Wietlispach Claussen
Therapeutic potential for orally administered type 1 interferons.
June 2000, Pharmaceutical science & technology today,
D Wietlispach Claussen
[Absorption, distribution and excretion of 3H--chenodeoxycholic acid (CDCA) in mice (author's transl)].
March 1981, Yao xue xue bao = Acta pharmaceutica Sinica,
D Wietlispach Claussen
Chenodeoxycholic acid (CDCA) versus ursodeoxycholic acid (UDCA): a comparison of their effects in pregnant rats.
July 1980, Archives internationales de pharmacodynamie et de therapie,
Copied contents to your clipboard!